BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12210877)

  • 1. [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.
    Pal PK; Leung J; Hedrich K; Samii A; Lieberman A; Nausieda PA; Calne DB; Breakefield XO; Klein C; Stoessl AJ
    Mov Disord; 2002 Jul; 17(4):789-94. PubMed ID: 12210877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
    Thobois S; Ribeiro MJ; Lohmann E; Dürr A; Pollak P; Rascol O; Guillouet S; Chapoy E; Costes N; Agid Y; Remy P; Brice A; Broussolle E;
    Arch Neurol; 2003 May; 60(5):713-8. PubMed ID: 12756135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.
    Hilker R; Klein C; Ghaemi M; Kis B; Strotmann T; Ozelius LJ; Lenz O; Vieregge P; Herholz K; Heiss WD; Pramstaller PP
    Ann Neurol; 2001 Mar; 49(3):367-76. PubMed ID: 11261512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
    Stormezand GN; Chaves LT; Vállez García D; Doorduin J; De Jong BM; Leenders KL; Kremer BPH; Dierckx RAJO
    Neuroimage Clin; 2020; 25():102161. PubMed ID: 31981888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study.
    Pavese N; Khan NL; Scherfler C; Cohen L; Brooks DJ; Wood NW; Bhatia KP; Quinn NP; Lees AJ; Piccini P
    Mov Disord; 2009 Nov; 24(15):2260-6. PubMed ID: 19845000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations.
    Portman AT; Giladi N; Leenders KL; Maguire P; Veenma-van der Duin L; Swart J; Pruim J; Simon ES; Hassin-Baer S; Korczyn AD
    Neurology; 2001 Jun; 56(12):1759-62. PubMed ID: 11425950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18 F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations.
    Broussolle E; Lücking CB; Ginovart N; Pollak P; Remy P; Dürr A
    Neurology; 2000 Sep; 55(6):877-9. PubMed ID: 10994015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease.
    Menza MA; Mark MH; Burn DJ; Brooks DJ
    J Neuropsychiatry Clin Neurosci; 1995; 7(2):176-9. PubMed ID: 7626960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.
    Otsuka M; Ichiya Y; Hosokawa S; Kuwabara Y; Tahara T; Fukumura T; Kato M; Masuda K; Goto I
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):898-904. PubMed ID: 1744644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations.
    Wu RM; Shan DE; Sun CM; Liu RS; Hwu WL; Tai CH; Hussey J; West A; Gwinn-Hardy K; Hardy J; Chen J; Farrer M; Lincoln S
    Mov Disord; 2002 Jul; 17(4):670-5. PubMed ID: 12210855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
    Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
    Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia.
    Binkofski F; Reetz K; Gaser C; Hilker R; Hagenah J; Hedrich K; van Eimeren T; Thiel A; Büchel C; Pramstaller PP; Siebner HR; Klein C
    Neurology; 2007 Aug; 69(9):842-50. PubMed ID: 17724286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
    Blesa J; Juri C; Collantes M; Peñuelas I; Prieto E; Iglesias E; Martí-Climent J; Arbizu J; Zubieta JL; Rodríguez-Oroz MC; García-García D; Richter JA; Cavada C; Obeso JA
    Neurobiol Dis; 2010 Jun; 38(3):456-63. PubMed ID: 20304066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
    Khan NL; Brooks DJ; Pavese N; Sweeney MG; Wood NW; Lees AJ; Piccini P
    Brain; 2002 Oct; 125(Pt 10):2248-56. PubMed ID: 12244082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
    Carbon M; Ma Y; Barnes A; Dhawan V; Chaly T; Ghilardi MF; Eidelberg D
    Neuroimage; 2004 Apr; 21(4):1497-507. PubMed ID: 15050574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
    Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
    Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.
    Ribeiro MJ; Thobois S; Lohmann E; du Montcel ST; Lesage S; Pelissolo A; Dubois B; Mallet L; Pollak P; Agid Y; Broussolle E; Brice A; Remy P;
    J Nucl Med; 2009 Aug; 50(8):1244-50. PubMed ID: 19617340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.
    Hilker R; Klein C; Hedrich K; Ozelius LJ; Vieregge P; Herholz K; Pramstaller PP; Heiss WD
    Neurosci Lett; 2002 Apr; 323(1):50-4. PubMed ID: 11911988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
    Scherfler C; Khan NL; Pavese N; Eunson L; Graham E; Lees AJ; Quinn NP; Wood NW; Brooks DJ; Piccini PP
    Brain; 2004 Jun; 127(Pt 6):1332-42. PubMed ID: 15090472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.